Тема - темы
Humans , Male , Female , Adult , Young Adult , Sweetening Agents/adverse effects , Neoplasms/chemically induced , Neoplasms/epidemiology , Aspartame/adverse effects , Risk Factors , Cohort Studies , DietТема - темы
Humans , Middle Aged , Aged , Aged, 80 and over , Vitamin D , Cardiovascular Diseases/prevention & control , Cardiovascular Diseases/drug therapy , Mortality , Cholecalciferol/therapeutic use , Australia/epidemiology , Vitamins/therapeutic use , Randomized Controlled Trials as Topic , Dietary SupplementsТема - темы
Humans , Adult , Young Adult , Vitamin D/blood , Vitamin D Deficiency/diagnosis , Vitamins/therapeutic use , Mass Screening/adverse effects , Cholecalciferol/therapeutic use , Vitamin D/analogs & derivatives , Vitamin D Deficiency/complications , Vitamin D Deficiency/mortality , Vitamin D Deficiency/blood , Accidental Falls , Fractures, Bone/prevention & control , Asymptomatic Diseases , Systematic Reviews as TopicРеферат
En Argentina, tres de las vacunas contra el COVID-19 autorizadas por la entidad regulatoria local se aplican en menores de edad: la vacuna desarrollada por Sinopharm (BBIBP-CorV) para niños de 3 años o más, y las desarrolladas por Moderna (ARNm 1273) y Pfizer (BNT162b2) a partir de los 12 años. Dado que estas recomendaciones no coinciden exactamente con las emitidas por diferentes organismos internacionales y debido al corto plazo de seguimiento de los ensayos publicados, surgieron dudas fundamentalmente en relación a su seguridad. En este artículo, los autores sintetizan la evidencia disponible hasta el momento sobre las vacunas aplicadas en niños, niñas y adolescentes en nuestro país, basada en informes preliminares de ensayos clínicos y reportes de vigilancia epidemiológica. (AU)
In Argentina, three of the COVID-19 vaccines authorized by the local regulatory entity are applied to minors: the vaccine developed by Sinopharm (BBIBP-CorV) for children 3 years of age or older, and those developed by Moderna (RNAm1273) and Pfizer (BNT162b2) from the age of 12 and onwards. Given that these recommendations do not coincide exactly with those issued by different international organizations and due to the short follow-up period of the published trials, doubts arose fundamentally in relation to their safety. In this article, the authors summarize the evidence available to date on vaccines applied to children and adolescents in our country, based on preliminary studies of clinical trials and epidemiological surveillance reports. (AU)